Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary antibody-drug ...
The Biden administration will propose a new rule to ban credit score companies from considering medical debt when they compile Americans' credit reports. The company expects to deliver $120 to $140 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback